DocGo Inc (Nasdaq: DCGO), a leading provider of last-mile mobile health services, announced today that Anthony Capone, Chief Executive Officer will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12 at 10:30AM Pacific Time. A webcast of the event will be available on the investor relations section of DocGo’s website at https://ir.docgo.com/.
Also, Lee Bienstock, President and Chief Operating Officer and Norm Rosenberg, Chief Financial Officer will present at the Needham Annual Growth Conference in New York on Tuesday, January 10, 2023 at 11:00AM Eastern Time. A webcast of the event will be available on the investor relations section of DocGo’s website at https://ir.docgo.com/.
About DocGo
DocGo is a leading provider of last-mile mobile care services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with Ambulnz by DocGo's integrated medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
Last Trade: | US$1.50 |
Daily Change: | -0.06 -3.85 |
Daily Volume: | 588,526 |
Market Cap: | US$148.650M |
May 08, 2025 February 27, 2025 February 19, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load